Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cysteamine plus standard therapy in hospitalized COVID-19 pneumonia
2024-516800-40-00Phase 2Authorised
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cysteamine in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Planned start Oct 2024; status: authorised.
02
Drugs
cysteamine
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on 2024-516800-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516800-40-00.